Anaplastic Lymphoma Kinase Inhibitors Market

List of Tables
Table 1. Anaplastic Lymphoma Kinase Inhibitors CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Anaplastic Lymphoma Kinase Inhibitors Market Trends
Table 3. Anaplastic Lymphoma Kinase Inhibitors Market Drivers
Table 4. Anaplastic Lymphoma Kinase Inhibitors Market Challenges
Table 5. Anaplastic Lymphoma Kinase Inhibitors Market Restraints
Table 6. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Anaplastic Lymphoma Kinase Inhibitors Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Anaplastic Lymphoma Kinase Inhibitors Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Anaplastic Lymphoma Kinase Inhibitors Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Manufacturer, 2017-2022
Table 13. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Manufacturer, (MT), 2017-2022
Table 14. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Manufacturer, 2017-2022
Table 15. Global Anaplastic Lymphoma Kinase Inhibitors Price by Manufacturer (2017-2022) & (USD/MT)
Table 16. Global Anaplastic Lymphoma Kinase Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Anaplastic Lymphoma Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2021)
Table 18. Top Players of Anaplastic Lymphoma Kinase Inhibitors in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Type
Table 20. Date of International Manufacturers Enter into Anaplastic Lymphoma Kinase Inhibitors Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Anaplastic Lymphoma Kinase Inhibitors Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Anaplastic Lymphoma Kinase Inhibitors Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Anaplastic Lymphoma Kinase Inhibitors Sales by Players, (MT), 2020, 2021 & 2022
Table 26. United States Anaplastic Lymphoma Kinase Inhibitors Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2017-2022) & (MT)
Table 29. Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume Forecast by Region (2023-2028) & (MT)
Table 30. Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2017-2028) & (MT)
Table 33. North America Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2017-2028) & (MT)
Table 35. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2017-2028) & (MT)
Table 37. Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2017-2028) & (MT)
Table 39. Latin Americaa Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2017-2028) & (MT)
Table 41. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Betta Pharmaceutcials Co., Ltd. Corporation Information
Table 43. Betta Pharmaceutcials Co., Ltd. Description and Business Overview
Table 44. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 45. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 46. Betta Pharmaceutcials Co., Ltd. Recent Development
Table 47. Crtierium, Inc. Corporation Information
Table 48. Crtierium, Inc. Description and Business Overview
Table 49. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 50. Crtierium, Inc. Product
Table 51. Crtierium, Inc. Recent Development
Table 52. F.Hoffman-La Roche Ltd. Corporation Information
Table 53. F.Hoffman-La Roche Ltd. Description and Business Overview
Table 54. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 55. F.Hoffman-La Roche Ltd. Product
Table 56. F.Hoffman-La Roche Ltd. Recent Development
Table 57. Helsinn Therapeutics Corporation Information
Table 58. Helsinn Therapeutics Description and Business Overview
Table 59. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 60. Helsinn Therapeutics Product
Table 61. Helsinn Therapeutics Recent Development
Table 62. Novartis AG. Corporation Information
Table 63. Novartis AG. Description and Business Overview
Table 64. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 65. Novartis AG. Product
Table 66. Novartis AG. Recent Development
Table 67. Oncoethix GmbH Corporation Information
Table 68. Oncoethix GmbH Description and Business Overview
Table 69. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 70. Oncoethix GmbH Product
Table 71. Oncoethix GmbH Recent Development
Table 72. Pfizer, Inc. Corporation Information
Table 73. Pfizer, Inc. Description and Business Overview
Table 74. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 75. Pfizer, Inc. Product
Table 76. Pfizer, Inc. Recent Development
Table 77. Takeda Pharmaceutical Co., Ltd. Corporation Information
Table 78. Takeda Pharmaceutical Co., Ltd. Description and Business Overview
Table 79. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 80. Takeda Pharmaceutical Co., Ltd. Product
Table 81. Takeda Pharmaceutical Co., Ltd. Recent Development
Table 82. Xcovery Holding Company, LLC Corporation Information
Table 83. Xcovery Holding Company, LLC Description and Business Overview
Table 84. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 85. Xcovery Holding Company, LLC Product
Table 86. Xcovery Holding Company, LLC Recent Development
Table 87. Tesaro, Inc. Corporation Information
Table 88. Tesaro, Inc. Description and Business Overview
Table 89. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 90. Tesaro, Inc. Product
Table 91. Tesaro, Inc. Recent Development
Table 92. Key Raw Materials Lists
Table 93. Raw Materials Key Suppliers Lists
Table 94. Anaplastic Lymphoma Kinase Inhibitors Customers List
Table 95. Anaplastic Lymphoma Kinase Inhibitors Distributors List
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Anaplastic Lymphoma Kinase Inhibitors Product Picture
Figure 2. Global Anaplastic Lymphoma Kinase Inhibitors Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Anaplastic Lymphoma Kinase Inhibitors Market Size 2017-2028 (US$ Million)
Figure 4. Global Anaplastic Lymphoma Kinase Inhibitors Sales 2017-2028 (MT)
Figure 5. United States Anaplastic Lymphoma Kinase Inhibitors Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Anaplastic Lymphoma Kinase Inhibitors Market Size 2017-2028 (US$ Million)
Figure 7. United States Anaplastic Lymphoma Kinase Inhibitors Sales 2017-2028 (MT)
Figure 8. United States Anaplastic Lymphoma Kinase Inhibitors Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Anaplastic Lymphoma Kinase Inhibitors Market Share in Global, in Volume (MT) 2017-2028
Figure 10. Anaplastic Lymphoma Kinase Inhibitors Report Years Considered
Figure 11. Product Picture of Crizotinib
Figure 12. Product Picture of Ceritinib
Figure 13. Product Picture of Alectinib Hydrochloride
Figure 14. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Type in 2022 & 2028
Figure 15. Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Type (2017-2028) & (US$ Million)
Figure 16. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type (2017-2028)
Figure 17. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028) & (MT)
Figure 18. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type (2017-2028)
Figure 19. Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2017-2028) & (USD/MT)
Figure 20. United States Anaplastic Lymphoma Kinase Inhibitors Market Share by Type in 2022 & 2028
Figure 21. United States Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type (2017-2028)
Figure 23. United States Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2017-2028) & (MT)
Figure 24. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type (2017-2028)
Figure 25. United States Anaplastic Lymphoma Kinase Inhibitors Price by Type (2017-2028) & (USD/MT)
Figure 26. Product Picture of NSCLC
Figure 27. Product Picture of Breast Cancer
Figure 28. Product Picture of Colorectal Cancer
Figure 29. Product Picture of Neuroblastoma
Figure 30. Product Picture of Ovarian Cancer
Figure 31. Product Picture of Others
Figure 32. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Application in 2022 & 2028
Figure 33. Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Application (2017-2028) & (US$ Million)
Figure 34. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application (2017-2028)
Figure 35. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028) & (MT)
Figure 36. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application (2017-2028)
Figure 37. Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2017-2028) & (USD/MT)
Figure 38. United States Anaplastic Lymphoma Kinase Inhibitors Market Share by Application in 2022 & 2028
Figure 39. United States Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Application (2017-2028) & (US$ Million)
Figure 40. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application (2017-2028)
Figure 41. United States Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2017-2028) & (MT)
Figure 42. United States Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application (2017-2028)
Figure 43. United States Anaplastic Lymphoma Kinase Inhibitors Price by Application (2017-2028) & (USD/MT)
Figure 44. North America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume Growth Rate 2017-2028 (MT)
Figure 45. North America Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 46. U.S. Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. Canada Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Volume Growth Rate 2017-2028 (MT)
Figure 49. Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 50. Germany Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. France Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. U.K. Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Italy Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Russia Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Volume Growth Rate 2017-2028 (MT)
Figure 56. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 57. China Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Japan Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. South Korea Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. India Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Australia Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Taiwan Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Indonesia Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Thailand Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Malaysia Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Philippines Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume Growth Rate 2017-2028 (MT)
Figure 68. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 69. Mexico Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Brazil Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Argentina Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Volume Growth Rate 2017-2028 (MT)
Figure 73. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 74. Turkey Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Saudi Arabia Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. U.A.E Anaplastic Lymphoma Kinase Inhibitors Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 77. Anaplastic Lymphoma Kinase Inhibitors Value Chain
Figure 78. Anaplastic Lymphoma Kinase Inhibitors Production Process
Figure 79. Channels of Distribution
Figure 80. Distributors Profiles
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed